Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05438420 · ClinicalTrials.gov registry record · Phase 1
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
A Phase 1 study of Gastric Cancer and Cervical Cancer, sponsored by Qurient Co..
- Active
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 7
- Study locations
NCT05438420: Active Phase 1 study of Gastric Cancer and Cervical Cancer, sponsored by Qurient Co..
NCT05438420 is a Phase 1 study of Gastric Cancer and Cervical Cancer that is active but no longer recruiting, run by Qurient Co.. The registered enrollment target is 120 participants, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (62% lower). The trial reports 7 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05438420, a Phase 1 study of Gastric Cancer and Cervical Cancer, is active but no longer recruiting, sponsored by Qurient Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Q702
Study Locations (7)
Other
- CHA Bundang Medical Center - Seongnam-si
- Asan Medical Center - Seoul
- Samsung Medical Center - Seoul
- Seoul National University Hospital - Seoul
- Severance Hospital - Seoul
California
- University of Southern California - Los Angeles
Kentucky
- Norton Cancer Institute - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-01-12 |
| Est. Completion | 2028-03-30 |
| Phase | Phase 1 |
What the registry record for NCT05438420 still lists
NCT05438420 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (62% lower).
The record links to 4 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05438420 lists 7 locations in 3 states (Other, California, Kentucky).
Frequently Asked Questions
What is clinical trial NCT05438420 about?
NCT05438420 is a clinical study titled "Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors". This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers.
What is the current status of trial NCT05438420?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2023-01-12. Estimated completion is 2028-03-30.
What conditions does trial NCT05438420 study?
This clinical trial studies the following conditions: Gastric Cancer, Cervical Cancer, Esophageal Cancer, Hepatocellular Cancer.
What interventions are being tested in trial NCT05438420?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Q702 (DRUG).
Who is sponsoring clinical trial NCT05438420?
This trial is sponsored by Qurient Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05438420 being conducted?
This trial has 7 study locations across California, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05438420's enrollment target sits among peer trials
120 74th of 153 higher than 79 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI